A Letter from CDI President & CEO Craig Strasnick To our Healthcare Partners and Friends of CDI, As we begin the New Year, we wanted to take a moment to reflect on the unprecedented 2020 and communicate how we are going to continue to align with the needs of our provider partners and their patients…
We are excited to announce that our enhanced website is now live with a streamlined, modern design, improved functionality, and easy access to essential information to help providers make well-informed decisions about diagnosing and treating functional GI disorders. Check out some of the new website features: Enriched solution pages that include testing information, instructions for use…
The COVID-19 pandemic has played a major role in the medical field and has altered the lives of patients’ throughout the world. Commonwealth Diagnostics International (CDI) co-hosted Epicured’s Partners in Health November 2020 Clinical Webinar featuring a panel of Gastroenterology experts who explored trends and best practices for diagnosing and treating functional GI Disorders in a…
Commonwealth Diagnostics International, Inc (CDI) has renewed their commitment to the Rome Foundation, an independent 501(c)3 organization whose mission is to improve the lives of people with functional GI disorders. The foundation provides support for activities geared towards data and educational information, which assists in the diagnosis and treatment of Disorders of Gut Brain Interactions. Millions of…
A Letter from CDI President Craig Strasnick: Commonwealth Diagnostics International, Inc. (CDI) today announced its commitment to assist in the continuity of care for the millions of Gastrointestinal sufferers in the United States. The healthcare delivery system is being pushed to the brink of its capacity, and these times have brought with them a significantly…
The Improved Sample Collection Method Expands Access to the Blood Test for Diagnosing DiarrheaPredominant and Mixed-Type Irritable Bowel Syndrome SALEM, MA February 1, 2020 – Commonwealth Diagnostics International (CDI), Inc., an international diagnostic service provider specializing in functional gastrointestinal disorders, recently announced the commercial re-launch of IBSchek®, the first clinically validated biomarker blood test for…
Salem, MA – January 10, 2020 – Commonwealth Diagnostics International, Inc. (CDI) is pleased to participate in a clinical trial with the University of Michigan, one of the largest gastroenterology practices in the country and a leader in the GI community. The clinical trial, Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea (IBS-D),…
Commonwealth Diagnostics International, Inc. (CDI) is pleased to announce its participation in the U.S. Department of Veterans Affairs’ (the VA’s) Community Care Network (CCN). The CCN is the VA’s direct link with specialized community providers, like CDI, to ensure that over 9 million enrolled Veterans receive adequate choice of and access to proper, timely, and…
Commonwealth Diagnostics International, Inc. (CDI) is pleased to announce its participation in the Blue Cross Blue Shield of Massachusetts Network. CDI is a diagnostic laboratory located in Salem, Massachusetts that offers a variety of products, services, and technologies that aid in the diagnosis of gastrointestinal disorders such as Small Intestinal Bacterial Overgrowth (SIBO) and Irritable…
Commonwealth Diagnostics International (CDI), Inc., an international diagnostic service provider specializing in functional gastrointestinal disorders, recently announced the commercial re-launch of IBSchek™, the first clinically validated blood test for diarrhea-predominant and mixed-type Irritable Bowel Syndrome (IBS-D, IBS-M). CDI will officially re-launch IBSchek to the gastroenterology community at Digestive Disease Week in Washington, DC in June…
